Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jaktinib plus Azacitidine in MDS/MPN with Myelofibrosis
NCT04866056Phase 2Terminated
- Sponsor
- Zelgen
- Start
- Sep 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of jaktinib in myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), myelofibrosis (MF), sponsored by Zelgen. Started Sep 2021; status: terminated.
02
Drugs
jaktinib
03
Conditions
myelodysplastic syndrome (MDS)myeloproliferative neoplasms (MPN)myelofibrosis (MF)
Beyond the preview
Go deeper on NCT04866056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04866056.